Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


The purpose of this study is to pilot-test a tailored telemetric intervention to improve adherence to medications in adults who had a liver transplant and are presently non-adherent (as measured by tacrolimus levels).

Study summary:

Adult patients who received a liver transplant and for whom there are at least 3 tacrolimus blood levels within the last year are eligible for the study. Patients will be recruited from amongst the roster of liver transplant recipients treated at the Recanati-Miller Transplant Institute at Mount Sinai. The intervention will be pilot-tested on up to 15 non-adherent patients. Patients will be identified using an innovative biomarker for non-adherence-by calculating the degree of fluctuation between individual medication blood levels. The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach that accommodates specific patient needs. The approach includes a focus on psychological avoidance.


Inclusion Criteria: - The patient is at least 18 years of age. - The patient received a liver transplant at least 2 years prior to initiation of the research protocol. - The patient is able to provide consent (i.e. is not encephalopathic or does not have significant cognitive impairment). Consent may be obtained either by phone or in person (following a script) and is documented by the researcher. - The patient is prescribed tacrolimus (either brand or generic formulation). - The patient is not receiving Hepatitis C treatment during the intervention (given this can affect levels of tacrolimus and adherence behaviors) - Thee patient has been seen in the liver transplant clinic at least once in the last two years. - The patient's MLVI value was ≥ 2, with at least 3 levels present to make this determination. Only tacrolimus levels drawn in the outpatient setting will be included in SD calculations. Tacrolimus levels in the inpatient setting (i.e. during a hospitalization) will be excluded. - The patient speaks English or Spanish at a level that allows him/her to understand the study procedures and consent to the study. Exclusion Criteria: - The patient received a liver transplant less than 2 years prior to enrollment. - The patient received a dual transplant (i.e. liver and kidney). - The treating physician has instructed the patient not to obtain tacrolimus levels for at least one year in the past year. - The patient does not understand the study procedures. This will be verified by asking the patient to repeat the study procedures. - The patient is actively psychotic or severely disoriented due to any cause, including hepatic encephalopathy (temporary exclusion) or severe cognitive impairment. - The patient is not medically stable or is hospitalized (temporary exclusion until stabilized).



Primary Contact:

Principal Investigator
Eyal Shemesh, MD
Icahn School of Medicine at Mount Sinai

Backup Contact:


Location Contact:

New York, New York 10029
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.